Abstract: Objective To investigate the pharmaceutical interventions in one case olapari-induced grade Ⅳ myelopathic depression by clinical pharmacists, and to provide reference for clinical safe and rational drug use. Methods Clinical pharmacists participated in the pharmaceutical care and adverse reaction management of one case of olapari-induced grade Ⅳ myeliopathic depression, regularly monitored and assessed adverse reaction symptoms, biochemical indexes and coagulation function of the patient, initiated immediate symptomatic treatment, and recommended individualized medication by referring to domestic and foreign literature and the consensus on guidelines for management of adverse reactions caused by PARP inhibitors. Results Clinical pharmacists worked in close collaboration with physicians to administer olaparil to this ovarian cancer patient to manage her adverse reactions, and assisted physicians in optimizing and restarting the treatment plan. Pharmacists followed up this patient for more than 8 months, during which time her blood biochemistry was within the reference range, tumor condition was stable, and no obvious grade Ⅱ or above myelopathic suppression occurred again. Conclusion The involvement of clinical pharmacists in drug monitoring and adverse reaction management during olaparil maintenance therapy of ovarian cancer patients, and in adjusting individualized medication plans can promote rational, safe and effective drug use for patients.

Key words: olaparib, ovarian cancer, myelosuppression, adverse drug reaction, pharmaceutical care